| Bioactivity | Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD)[1][2][3]. |
| In Vivo | Memantine (1, 5 and 10, 15 mg/kg; i.p.; daily for 15-20 days) significantly decreased the large LTP recorded in hippocampal slices from aged animals[2].Memantine (1-3 mg/kg; per os (p.o.)) for 14 days significantly improves depressive-like behaviors in olfactory bulbectomized (OBX) mice, as assessed using the tail-suspension and forced-swim tests[3]. Animal Model: |
| Name | Memantine |
| CAS | 19982-08-2 |
| Formula | C12H21N |
| Molar Mass | 179.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marotta G, et al. Memantine Derivatives as Multitarget Agents in Alzheimer's Disease. Molecules. 2020;25(17):4005. Published 2020 Sep 2. [2]. Pinho J, et al. Enhanced LTP in aged rats: Detrimental or compensatory?. Neuropharmacology. 2017;114:12-19. [3]. Moriguchi S, et al. Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice. Neuroscience. 2020;442:264-273. |